Which medications in the drug class Antidiabetics, Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors are used in the treatment of Diabetic Nephropathy?

Updated: Oct 09, 2019
  • Author: Vecihi Batuman, MD, FASN; Chief Editor: Romesh Khardori, MD, PhD, FACP  more...
  • Print

Antidiabetics, Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors

Agents in this category inhibit renal glucose absorption in the proximal tubule, the site in the kidney where approximately 90% of glucose reabsorption occurs. This leads to increased excretion of glucose in the urine.

Canagliflozin (Invokana)

Canagliflozin is a selective sodium-glucose transporter-2 (SGLT2) inhibitor. SGLT-2 inhibition lowers the renal glucose threshold (ie, the plasma glucose concentration that exceeds the maximum glucose reabsorption capacity of the kidney); lowering the renal glucose threshold results in increased urinary glucose excretion. Indicated as an adjunct to diet and exercise, canagliflozin therapy is aimed at improving glycemic control in adults with type 2 DM. In addition, in adults with type 2 DM and diabetic nephropathy with albuminuria of more than 300 mg/day, canagliflozin is indicated to lower the chances of end-stage renal disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!